Program 52: Kidney Cancer

肾癌项目 项目摘要/摘要 肾癌计划对肾脏肿瘤的分子基础进行创新的基础研究。 当前资助期内的科学努力侧重于确定早期有意义的生物标记物 检测和预后，疾病生物学的基本机制和新的治疗靶点 不同的肾癌人群，并改进了用于初步验证这些发现的临床前模型。 该计划的具体目标是1)识别和验证肾癌的新靶点，并建立 用于测试新药物的临床前模型；2)确定反应和毒性的分子和生物学预测因子 用于治疗；3)利用计划和孢子基础设施促进药物和设备的开发；以及4) 找出增加肾癌风险的因素，预测肾癌的发展和复发。该计划 有38名成员，代表7个DF/CC机构和8个学术部门。2014年的同行- 经审查的赠款资金归因于该方案，总成本为130万美元，来自NCI的120万美元 来自其他赞助商。在当前的资助期间，肾癌计划成员发表了742 与癌症相关的论文。其中36%是机构间的，14%是方案内的，51%是 两个或更多DF/CC成员之间的方案间协作。总体而言，如果算一次，27% 粮食计划/方案协调委员会出版物的大多数是方案间合作。

Kidney Cancer Program Project Summary / Abstract The Kidney Cancer Program performs innovative basic research into the molecular basis of kidney tumors. Scientific efforts within the current funding period have focused on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology and novel therapeutic targets for the various kidney cancer populations, and improved preclinical models for preliminary validation of these findings. The specific aims of the program are to 1) Identify and validate novel targets in kidney cancer, and establish pre-clinical models for testing new agents; 2) Identify molecular and biologic predictors of response and toxicity to therapy; 3) Leverage Program and SPORE infrastructure to facilitate drug and device development; and 4) Identify factors that increase the risk, predict the development and recurrence of kidney cancer. The program has 38 members, representing seven DF/HCC institutions and 8 academic departments. In 2014 peer- reviewed grant funding attributed to the Program was $1.3 million in total costs from the NCI and $1.2 million from other sponsors. During the current funding period, Kidney Cancer Program members published 742 cancer-relevant papers. Of these 36% were inter-institutional, 14% were intra-programmatic, and 51% were inter-programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter-programmatic collaborations.